Raymond James Downgrades Abbott Labs (ABT) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Abbott (ABT) Sees Q4 Sales Growth in Low-Mid Single-Digit Range
October 17, 2012 9:45 AM EDTAbbott Laboratories (NYSE: ABT) said to see fourth-quarter sales growth in the low-to-mid single-digit range. Comments were made on the company's conference call this morning following... More
Abbott Laboratories (ABT) Tops Q3 EPS by 2c; Narrows FY12 EPS Outlook
October 17, 2012 7:45 AM EDTAbbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $9.77 billion versus the consensus estimate of $9.93 billion.
Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.... More
